Detalhe da pesquisa
1.
Effectiveness of convective water vapor energy therapy versus prostatic urethral lift for symptomatic benign prostatic hyperplasia: a systematic review and indirect comparison.
World J Urol
; 39(9): 3207-3215, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-33515055
2.
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
J Urol
; 189(1 Suppl): S45-50, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-23234631
3.
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.
J Urol
; 187(3): 889-93, 2012 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-22245322
4.
Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer.
J Urol
; 186(2): 482-6, 2011 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-21679977
5.
Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.
J Urol
; 186(6): 2239-44, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-22014807
6.
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
J Urol
; 184(4): 1316-21, 2010 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-20723926
7.
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
Cancer Res
; 64(20): 7355-60, 2004 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-15492256
8.
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Cancer Res
; 62(18): 5365-9, 2002 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12235008
9.
Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
Cancer Res
; 62(13): 3649-53, 2002 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-12097269
10.
Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells.
Oncogene
; 23(46): 7651-9, 2004 Oct 07.
Artigo
Inglês
| MEDLINE | ID: mdl-15354178
11.
Prostate specific antigen as a clinical biomarker for prostate cancer: what's the take home message?
Cancer Biol Ther
; 4(4): 371-5, 2005 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-15846084
12.
Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.
Clin Cancer Res
; 9(16 Pt 1): 6046-51, 2003 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-14676131
13.
Proven and unproven therapy for benign prostatic hyperplasia.
N Engl J Med
; 354(6): 632-4, 2006 Feb 09.
Artigo
Inglês
| MEDLINE | ID: mdl-16467551
14.
Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop.
Urology
; 83(5): 975-8, 2014 May.
Artigo
Inglês
| MEDLINE | ID: mdl-24661332
15.
Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop.
Urology
; 83(2): 262-4, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24332121
16.
Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer.
Endocrinology
; 153(3): 1070-81, 2012 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-22294742
17.
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.
J Cachexia Sarcopenia Muscle
; 2(3): 153-161, 2011 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-22031847
18.
19.
Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening.
J Urol
; 171(6 Pt 1): 2234-8, 2004 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-15126793